Venetoclax and ibrutinib and drug combinations for CLL
Relapse in DLBCL - addressing the unmet need with brentuximab vedotin
Recent developments in the mutational landscape and molecular basis of AML
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al.